What is the BioFinder - Brown Study?
This is an observational study to learn more about assessing potential risk for developing Alzheimer’s disease (AD) using biomarker research.
The BioFinder-Brown study is a five-year study and involves procedures such as memory and thinking testing and assessments, Magnetic Resonance Imaging (MRI) Scans, Positron Emission Tomography (PET) scan, Retinal (Eye) Imaging scans, and blood draws. Some procedures such as additional PET scans and learning about your individual risk for AD will be optional for interested individuals. Approximately 200 cognitively normal participants between the ages of 50 to 80 years old will be enrolled at Butler Hospital’s Memory and Aging Program.
What is the purpose of the BioFinder - Brown Study?
This study aims to validate AD biomarker indicators in individuals who are healthy, yet may have a higher risk for developing AD. The study will also use these and other metrics to form improved methods to better assess risk for Alzheimer’s disease.
Men and women ages 50 to 80 years old with no memory impairment.
If you are interested in learning more about the BioFinder - Brown study, please call (401) 455-6402 or send an e-mail to email@example.com. Ask about the “BioFinder - Brown Trial.”